Suchergebnisse - "Hanley, Michael J"

PubPharm (44)

1

The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2019

von Tugnait, M. | Gupta, N. | Hanley, M. | +5

2

Clinical Pharmacology of Ixazomib : The First Oral Proteasome Inhibitor

enthalten in: Clinical pharmacokinetics | 2019

von Gupta, N. | Hanley, M. | Xia, C. | +3

3

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

enthalten in: Clinical pharmacokinetics | 2019

von Gupta, N. | Hanley, M. | Xia, C. | +3

4

Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

enthalten in: Clinical pharmacology and therapeutics | 2019

von Gupta, N. | Hanley, M. | Diderichsen, P. | +9

5

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

enthalten in: Clinical Pharmacology in Drug Development | 2019

von Tugnait, M. | Gupta, N. | Hanley, M. | +5

6

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

enthalten in: Clinical Pharmacology & Therapeutics | 2019

von Gupta, N. | Hanley, M. | Diderichsen, P. | +9

7

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

enthalten in: Clinical pharmacokinetics | 2018

von Gupta, N. | Hanley, M. | Xia, C. | +3

8

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2018

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

9

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor : Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

enthalten in: Journal of clinical pharmacology | 2018

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +13

10

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2018

von Hanley, M. | Gupta, N. | Venkatakrishnan, K. | +6

1
2
3
4
5
Nächster »
[5]